Mirati Therapeutics Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Mirati Therapeutics Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 31 Aug 2022 | Lorem |
| Mirati’s adagrasib has experts cautious if its durability of response can be extended in colorectal cancer | 30 Jul 2021 | Reynald Castaneda |
| Amgen and Mirati’s KRAS inhibitors’ efficacy and safety differences in NSCLC too preliminary to draw conclusions despite analyst enthusiasm, strong AA prospects, experts say | 25 Nov 2020 | Manasi Vaidya |
| Amgen and Mirati’s KRAS-targeting therapies’ PK differences in solid tumours may be clinically irrelevant for efficacy; both small molecule approaches edge antisense oligo mechanism, experts say | 10 Jun 2019 | Reynald Castaneda,Manasi Vaidya |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer